BRIEF-Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction

Reuters12-04

Dec 4 (Reuters) - Windtree Therapeutics Inc WINT.O:

WINDTREE ANNOUNCES PARTNERSHIP WITH NEW GROWTH ADVISORS TO LEVERAGE POSITIVE PHASE 2 ISTAROXIME STUDY IN CARDIOGENIC SHOCK FOR A POTENTIAL STRATEGIC TRANSACTION
WINDTREE THERAPEUTICS INC: ENGAGED NEW GROWTH ADVISORS AS ITS STRATEGIC ADVISOR TO LEAD A PROCESS IN RESPECT OF WINDTREE'S CARDIOVASCULAR PORTFOLIO
WINDTREE: IF A DEAL IS CONSUMMATED FOR CARDIOVASCULAR PORTFOLIO, PLANS TO USE SOME PROCEEDS TO SUPPORT ADVANCEMENT OF ONCOLOGY PLATFORM
WINDTREE THERAPEUTICS INC - LEE'S PHARMACEUTICALS TO START PHASE 3 IN ACUTE HEART FAILURE IN H1 2025
WINDTREE THERAPEUTICS INC - MAY RECEIVE UP TO $138 MILLION IN MILESTONES FROM LEE'S PHARMACEUTICALS

Source text: ID:nGNXb28vrr

Further company coverage: WINT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488199605?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-04 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488199605","market":"us","top_or_hot":-1,"title":"BRIEF-Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction</title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>Windtree <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>WINT.O</span>:</p><ul><li><p>WINDTREE ANNOUNCES PARTNERSHIP WITH NEW GROWTH ADVISORS TO LEVERAGE POSITIVE PHASE 2 ISTAROXIME STUDY IN CARDIOGENIC SHOCK FOR A POTENTIAL STRATEGIC TRANSACTION</p></li><li><p>WINDTREE THERAPEUTICS INC:  ENGAGED NEW GROWTH ADVISORS AS ITS STRATEGIC ADVISOR TO LEAD A PROCESS IN RESPECT OF WINDTREE'S CARDIOVASCULAR PORTFOLIO</p></li><li><p>WINDTREE:  IF A DEAL IS CONSUMMATED FOR CARDIOVASCULAR PORTFOLIO, PLANS TO USE SOME PROCEEDS TO SUPPORT ADVANCEMENT OF ONCOLOGY PLATFORM</p></li><li><p>WINDTREE THERAPEUTICS INC - LEE'S PHARMACEUTICALS TO START PHASE 3 IN ACUTE HEART FAILURE IN H1 2025</p></li><li><p>WINDTREE THERAPEUTICS INC - MAY RECEIVE UP TO $138 MILLION IN MILESTONES FROM LEE'S PHARMACEUTICALS</p></li></ul><p>Source text: <span>ID:nGNXb28vrr</span></p><p>Further company coverage: <span>WINT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-04 21:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUA8VG6WN:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic TransactionDec 4 (Reuters) - Windtree ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUA8VG6WN:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUA8VG6WN:1","article_id":"2488199605","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488199605","pubTimestamp":1733320553,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic TransactionDec 4 (Reuters) - Windtree Therape","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","WINT":"Windtree Therapeutics, Inc."},"translate_title":"简介-Windtree宣布与New Growth Advisors合作，利用Istaroxime在心源性休克方面的积极2期研究进行潜在的战略交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WINT":0.9},"content_text":"BRIEF-Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic TransactionDec 4 (Reuters) - Windtree Therapeutics Inc WINT.O:WINDTREE ANNOUNCES PARTNERSHIP WITH NEW GROWTH ADVISORS TO LEVERAGE POSITIVE PHASE 2 ISTAROXIME STUDY IN CARDIOGENIC SHOCK FOR A POTENTIAL STRATEGIC TRANSACTIONWINDTREE THERAPEUTICS INC:  ENGAGED NEW GROWTH ADVISORS AS ITS STRATEGIC ADVISOR TO LEAD A PROCESS IN RESPECT OF WINDTREE'S CARDIOVASCULAR PORTFOLIOWINDTREE:  IF A DEAL IS CONSUMMATED FOR CARDIOVASCULAR PORTFOLIO, PLANS TO USE SOME PROCEEDS TO SUPPORT ADVANCEMENT OF ONCOLOGY PLATFORMWINDTREE THERAPEUTICS INC - LEE'S PHARMACEUTICALS TO START PHASE 3 IN ACUTE HEART FAILURE IN H1 2025WINDTREE THERAPEUTICS INC - MAY RECEIVE UP TO $138 MILLION IN MILESTONES FROM LEE'S PHARMACEUTICALSSource text: ID:nGNXb28vrrFurther company coverage: WINT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488199605"}